Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Avandia Restrictions Hit GlaxoSmithKline Q3 profit

By Pharmaceutical Processing | October 21, 2010

LONDON (AP) — GlaxoSmithKline
reported a 3.5 percent drop in third-quarter earnings today due to generic
competition and a European ban on its diabetes drug Avandia, which was also
restricted in the United States.

For the three months ending Sept. 30, GSK reported a net profit of 1.29
billion pounds ($2.03 billion), compared to 1.34 billion pounds a year earlier.
Revenue rose 0.8 percent to 6.8 billion pounds on a reported basis, but were up
2 percent when not counting shifts in currency values.

The company raised its third-quarter dividend by 7 percent to 16 pence.

GSK shares, however, were down 1.6 percent at 1,272 pence following the
report.

In September, European regulators ordered Avandia off the market and the U.S.
Food and Drug Administration placed stringent restrictions on its use in the
United States, in both cases because of a heightened risk of heart attack
associated with the drug.

GSK booked a one-time charge of 147 million pounds related to Avandia,
including the expected return of 65 million pounds worth of the product. GSK
says future global sales of its once-blockbuster drug will be minimal.

The Avandia rulings and generic competition for Valtrex herpes medication
drove GSK sales down 8 percent in the United States and 9 percent in Europe, the
company said.

In the United States, GSK reported a 32 percent increase in vaccine sales, a
34 percent rise for cancer drugs and a 20 percent boost for Lovaza, its fish oil
pill to control triglyceride fats in the blood.

Chief Executive Andrew Whitty said the group estimated that third-quarter
revenue was reduced by 2 percent because of U.S. health care reform and European
government spending cuts.

Related Articles Read More >

Astellas
Astellas to spend $70M on new biotech campus in South San Francisco
Rainin
Mettler Toledo Rainin expands facilities in Vacaville, California
Elemental Machines
Elemental Machines aims to enlist lab freezers in fight against climate change 
Pfizer logo
Pfizer seeks to comply with voluntary Net-Zero Standard by 2040

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards